A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.
Latest Information Update: 26 May 2026
At a glance
- Drugs Tulisokibart (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms MK-7240-015
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 27 Apr 2026 Status changed from not yet recruiting to recruiting.
- 26 Mar 2026 New trial record